Sex-specific differences in diabetes prevention: a systematic review and meta-analysis.

Published

Journal Article (Review)

AIMS/HYPOTHESIS: In people with prediabetes, lifestyle interventions and glucose-lowering medications are effective in preventing the progression to type 2 diabetes. It is unclear whether differences in treatment effects between men and women need to be taken into consideration when choosing a preventive strategy for an individual person. METHODS: We systematically searched PubMed, the Cochrane Library, EMBASE, CINAHL, Web of Science, and reference lists of pertinent review articles from 1980 to June 2013. We conducted random effects meta-analyses of published and unpublished data to determine differences of treatment effects between men and women. RESULTS: Twelve randomised control trials (RCTs) provided sex-specific information on treatment effects. Compared with usual care, men and women who received lifestyle interventions had a lower rate of progression to type 2 diabetes (RR 0.60 [95% CI 0.35, 1.05] after 1 year; RR 0.63 [95% CI 0.51, 0.79] after 3 years); greater weight reduction (-2.45 kg; [95% CI -3.56, -1.33 kg] after 3 years); and greater reductions of fasting plasma glucose (-0.31 mmol/l [95% CI -0.48, -0.15] after 3 years) and 2 h post-challenge-glucose (-0.68 mmol/l [95% CI -1.03, -0.34] after 3 years). No statistically significant differences in treatment effects between men and women were apparent for any outcomes (p values of all comparisons ≥ 0.09). CONCLUSIONS/INTERPRETATION: Our study emphasises the importance of preventive interventions in people with prediabetes and indicates no differences of beneficial preventive effects on the incidence of type 2 diabetes and weight gain between men and women.

Full Text

Cited Authors

  • Glechner, A; Harreiter, J; Gartlehner, G; Rohleder, S; Kautzky, A; Tuomilehto, J; Van Noord, M; Kaminski-Hartenthaler, A; Kautzky-Willer, A

Published Date

  • February 2015

Published In

Volume / Issue

  • 58 / 2

Start / End Page

  • 242 - 254

PubMed ID

  • 25465437

Pubmed Central ID

  • 25465437

Electronic International Standard Serial Number (EISSN)

  • 1432-0428

Digital Object Identifier (DOI)

  • 10.1007/s00125-014-3439-x

Language

  • eng

Conference Location

  • Germany